MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research (AACR) today in a poster session titled, “XmAb™5574: an Fc-Engineered Anti-CD19 Monoclonal Antibody with In Vitro and In Vivo Efficacy against Lymphoma and Leukemia”. In the studies, XmAb5574 demonstrated enhanced anti-tumor activity in vitro and in vivo, and caused sustained B cell depletion in cynomolgus monkeys.
